Diabetes

The latest diabetes and endocrinology news from UNC Health Care and the UNC School of Medicine.

UNC researchers find two biomarkers linked to severe heart disease

UNC researchers find two biomarkers linked to severe heart disease

The finding published in PLoS One suggests that elevated oxidized LDL cholesterol and fructosamine – a measure of glycated proteins in blood sugar – are signposts for the development of severe coronary disease, especially in females.

UNC researchers find two biomarkers linked to severe heart disease - Read More…

Smart insulin patch could replace painful injections for diabetes

Smart insulin patch could replace painful injections for diabetes

A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.

Smart insulin patch could replace painful injections for diabetes - Read More…

UNC diabetes researcher featured on WRAL

UNC diabetes researcher featured on WRAL

TV segment focused diabetes prevention and screening and featured John Buse, MD, PhD, chief, Division of Endocrinology, executive associate dean for clinical research.

UNC diabetes researcher featured on WRAL - Read More…

Diabetes researcher earns ADA grant to design nanoparticles to control blood sugar

Diabetes researcher earns ADA grant to design nanoparticles to control blood sugar

The research by Zhen Gu, PhD, assistant professor in the UNC-NCSU joint department of biomedical engineering, aims to improve methods for delivering precise amounts of medications less frequently.

Diabetes researcher earns ADA grant to design nanoparticles to control blood sugar - Read More…

Diabetes researchers urge for new screening and management approach

Diabetes researchers urge for new screening and management approach

By treating people earlier, doctors could help diabetes patients avoid the most severe, life-threatening complications that stem from prolonged periods of elevated blood glucose.

Diabetes researchers urge for new screening and management approach - Read More…

Common diabetes drug not linked to short-term risk of pancreatic cancer

Common diabetes drug not linked to short-term risk of pancreatic cancer

UNC researchers overturn a controversial study about DPP-4 inhibitors – commonly prescribed diabetes medications.

Common diabetes drug not linked to short-term risk of pancreatic cancer - Read More…

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET!

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET!

Participating in the chat will be two diabetes experts and co-authors of a new American Diabetes Association position statement on the care of people with type 1 diabetes.

Join our #T1Dchat on Twitter – Aug. 19 at 1 p.m. ET! - Read More…

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program

The Bamberg Diabetes Transitional Care Study will utilize cutting-edge iPad technology to explore the impact and feasibility of different diabetes interventions for patients transitioning from the hospital to home.

MUSC and UNC-Chapel Hill join forces to test a diabetes outreach program - Read More…

Buse recognized as leading expert in type 2 diabetes

Buse recognized as leading expert in type 2 diabetes

John B. Buse, MD, PhD, chief of the division of endocrinology and director of the Diabetes Care Center, has been ranked as one of the world’s foremost experts in type 2 diabetes based on an analysis of publications in the National Library of Medicine’s MEDLINE database.

Buse recognized as leading expert in type 2 diabetes - Read More…

UNC and SAS join forces to personalize health care for better outcomes

Collaboration will leverage big data to help providers engage patients to manage diabetes, improve health

UNC and SAS join forces to personalize health care for better outcomes - Read More…

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes

The ENDO Trial is currently enrolling adults between the ages of 21 and 65 who have uncontrolled type 2 diabetes and are obese.

UNC begins clinical trial of EndoBarrier® for treatment of type 2 diabetes - Read More…

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy

Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.

UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy - Read More…

To test or not to test:  Blood glucose monitoring for patients with type 2 diabetes

To test or not to test: Blood glucose monitoring for patients with type 2 diabetes

The Patient-Centered Outcomes Research Institute awards UNC School of Medicine researchers more than $2 million to study glucose monitoring in non-insulin treated patients living with type 2 diabetes.

To test or not to test: Blood glucose monitoring for patients with type 2 diabetes - Read More…

Diabetes investigation in rats makes editor's pick in APS journal

An investigation into diabetes-related outcomes in a rat model, with senior author William Valdar, PhD, assistant professor of genetics at UNC, and first author Leah Solberg Woods, PhD, from the Medical College of Wisconsin, has made the editor's pick in this month's Physiological Genomics, a journal of the American Physiological Society.

Diabetes investigation in rats makes editor's pick in APS journal - Read More…

UNC's Dr. John Buse named to international diabetes prize selection jury

UNC's Dr. John Buse named to international diabetes prize selection jury

The 2013 Harold Hamm International Prize for Biomedical Research in Diabetes encourages research focused on progress toward a cure.

UNC's Dr. John Buse named to international diabetes prize selection jury - Read More…

Head-to-head trial of two diabetes drugs yields mixed results

Head-to-head trial of two diabetes drugs yields mixed results

Daily injections of liraglutide were slightly more effective than weekly injections of exenatide in lowering blood sugar and promoting weight loss. However, patients had fewer negative side effects on exenatide once weekly.

Head-to-head trial of two diabetes drugs yields mixed results - Read More…

Three UNC specialties nationally ranked by U.S. News

Three UNC specialties nationally ranked by U.S. News

Overall, eleven specialties at UNC Hospitals were recognized as nationally ranked or high performing by U.S. News & World Report in its annual "America's Best Hospitals" issue.

Three UNC specialties nationally ranked by U.S. News - Read More…

Antibodies reverse Type 1 diabetes in new immunotherapy study

Antibodies reverse Type 1 diabetes in new immunotherapy study

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease.

Antibodies reverse Type 1 diabetes in new immunotherapy study - Read More…

Join Dr. John Buse for live Facebook chat on diabetes

Join Dr. John Buse for live Facebook chat on diabetes

Dr. John Buse, director of the UNC Diabetes Care Center and chair of the National Diabetes Education Program, will host a live Facebook chat on diabetes management and prevention on Tuesday, May 22.

Join Dr. John Buse for live Facebook chat on diabetes - Read More…

Share This: